IQVIA Holdings Inc. Earnings Recaps
Q2 2026
Jul 30, 2026
The stock surged 16.1% post-earnings, driven by clear beats across revenue, adjusted EBITDA, and EPS, with organic and segment-level growth outpacing prior expectations and margins expanding earlier than anticipated.
Key takeaways
- Reported revenue grew 8.7% year-over-year, exceeding the high-end of guidance despite lower-than-expected FX tailwinds; organic growth accelerated to 6%.
- Adjusted EBITDA rose 9.2% year-over-year, surpassing the top end of guidance, supported by better-than-expected operational performance and margin improvements.
- Adjusted diluted EPS increased 12.1% to $3.15, also above guidance, reflecting strong underlying profitability.
- Clinical R&D bookings hit $3.15 billion, up 19% year-over-year and 27% sequentially, with a book-to-bill ratio of 1.22, signaling sustained demand momentum.
- Commercial segment organic growth accelerated to 5%, with analytics and consulting posting high-single-digit growth, driven by new drug launches and increased AI adoption.
Q1 2026
May 6, 2026
IQVIA Holdings Inc. shares rallied 9.6% post-earnings, primarily driven by a meaningful beat on both revenue and adjusted EPS versus guidance, supported by notable acceleration in organic growth across commercial and clinical segments.
Key takeaways
- Total revenue grew 8.4% year over year on a reported basis and 6% at constant currency, beating the high end of guidance.
- Adjusted diluted EPS of $2.90 exceeded the high end of guidance, up 7.4% year over year.
- Organic revenue growth accelerated significantly, with Commercial Solutions doubling and R&D Solutions tripling their respective growth rates year over year.
- Backlog reached a record $34.2 billion, with $8.9 billion expected to convert to revenue within twelve months, reflecting nearly 8% year-over-year growth.
- Strong client demand driven in part by AI integration, with 192 AI agents deployed covering 64 use cases and adoption by 19 of the top 20 pharma companies.
Q3 2025
Oct 28, 2025
IQVIA reported solid third-quarter 2025 results, with revenues and profits at the high end of guidance, driven by robust operational performance and impressive free cash flow.
Key takeaways
- Revenue growth of 5.2% year-over-year, with adjusted diluted EPS rising 5.6%.
- Record backlog of $32.4 billion, up 4.1% compared to the prior year, reflecting strong demand trends.
- Net bookings reached $2.6 billion, translating to a favorable net book-to-bill ratio of 1.15x, driven by improved customer demand.
- Continued strength in the TAS segment with successful drug launches contributing to overall results.
- Strong free cash flow this quarter marks the highest ever, highlighting effective working capital management.